Real World Andalusian Multicenter Data on Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 60
- 试验地点
- 10
- 主要终点
- Clinical improvement (risk profile)
研究概览
简要总结
This is an observational, ambrispective study of patients in real world clinical practice, who has pulmonary arterial hypertension in whom a prostacyclin IP receptor agonist (Selexipag) is initiated between 2017 and 2021.
The aim of this study answer the following questions:
- Changes in the mortality risk profile of these patients after treatment administration.
- Baseline characteristics of patients initiating Selexipag.
- Parameters used for risk stratification prior to treatment escalation.
- Events during follow-up.
No comparison group available
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •They agree to participate in the study by signing an informed consent form
排除标准
- •Decline to participate in the study
- •Patients living 6 months or less in the reference health area
- •Patients with active malignant tumors
研究组 & 干预措施
Cohort 1
Patients with pulmonary arterial hypertension on treatment with prostacyclin IP receptor agonists because they are at intermediate risk of mortality at one year
干预措施: No intervention - Observational study (Drug)
结局指标
主要结局
Clinical improvement (risk profile)
时间窗: 12 months
Percentage of patients reducing annual mortality risk profile according to ESC/ERS Clinical Practice Guidelines 2015 Risk Stratification.
次要结局
- Events(12 months)
- Risk stratification variables(Basaline)
研究者
Rafael Bravo Marqués
Medical Specialist, Department of Cardiology, Hospital Costa del Sol, Marbella (Malaga,) Spain
Hospital Costa del Sol